10.18.21
Middle-market private equity firm Gryphon Investors has signed an agreement to acquire Metagenics from Alticor Inc., the parent company of Amway and Access Business Group.
Founded in 1983 and based in Aliso Viejo, CA, Metagenics is a global nutritional supplement company that partners with healthcare practitioners to deliver personalized lifestyle solutions.
The transaction marks Gryphon’s third investment in consumer health products and first investment in the nutritional health category.
“Metagenics has a unique position as a leader among nutrition brands recommended by healthcare practitioners across its three core geographic markets,” said Gryphon Operating Partner Mike Ferry. “We are excited to invest behind the Metagenics mission, including helping their healthcare practitioner partners to support the health of their patients around the world.”
CEO Brent Eck will continue to lead Metagenics’ management team. As part of the transaction, Gryphon Executive Advisor Steve LaMonte will become executive chairman of the Metagenics Board. “We are delighted to partner with the team at Gryphon as we plan for long-term sustainable growth for the Metagenics brand around the world,” said Eck. “Gryphon brings a truly differentiated set of capabilities as a partner, and their investment will allow us to invest for the future, both organically and through strategic acquisitions.”
This will be the fourth investment on which Gryphon and LaMonte have partnered. He will be one of several Gryphon executive advisors to join the board along with Ferry, Gryphon Deal Partner Matt Farron, and Gryphon Managing Director Ryan Fagan.
“We’re happy to partner with a company that operates at the gold standard of scientific credibility, quality, innovation, and sourcing transparency,” said Fagan. “Both healthcare practitioners and their patients are increasingly focused on making proactive healthy lifestyle choices, and nutrition is a necessary part of that effort. Gryphon has been searching for the right platform to invest behind this movement for several years and we will continue to actively search for similar opportunities—potential acquisitions for Metagenics as well as incremental independent platforms in the health and wellness category.”
Financial terms of the deal were not disclosed. The transaction is expected to close in the fourth quarter of 2021.
Founded in 1983 and based in Aliso Viejo, CA, Metagenics is a global nutritional supplement company that partners with healthcare practitioners to deliver personalized lifestyle solutions.
The transaction marks Gryphon’s third investment in consumer health products and first investment in the nutritional health category.
“Metagenics has a unique position as a leader among nutrition brands recommended by healthcare practitioners across its three core geographic markets,” said Gryphon Operating Partner Mike Ferry. “We are excited to invest behind the Metagenics mission, including helping their healthcare practitioner partners to support the health of their patients around the world.”
CEO Brent Eck will continue to lead Metagenics’ management team. As part of the transaction, Gryphon Executive Advisor Steve LaMonte will become executive chairman of the Metagenics Board. “We are delighted to partner with the team at Gryphon as we plan for long-term sustainable growth for the Metagenics brand around the world,” said Eck. “Gryphon brings a truly differentiated set of capabilities as a partner, and their investment will allow us to invest for the future, both organically and through strategic acquisitions.”
This will be the fourth investment on which Gryphon and LaMonte have partnered. He will be one of several Gryphon executive advisors to join the board along with Ferry, Gryphon Deal Partner Matt Farron, and Gryphon Managing Director Ryan Fagan.
“We’re happy to partner with a company that operates at the gold standard of scientific credibility, quality, innovation, and sourcing transparency,” said Fagan. “Both healthcare practitioners and their patients are increasingly focused on making proactive healthy lifestyle choices, and nutrition is a necessary part of that effort. Gryphon has been searching for the right platform to invest behind this movement for several years and we will continue to actively search for similar opportunities—potential acquisitions for Metagenics as well as incremental independent platforms in the health and wellness category.”
Financial terms of the deal were not disclosed. The transaction is expected to close in the fourth quarter of 2021.
